Trial · NCT04789330
Norepinephrine vs Phenylephrine During General Anesthesia
NCT04789330, Phase 4, Completed, University of California, San Francisco; results first posted 2025-12-18
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Norepinephrine vs Phenylephrine During General Anesthesia. Trials, record NCT04789330. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT04789330
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Norepinephrine vs Phenylephrine During General Anesthesia
- NCT number
- NCT04789330
- Status
- Completed
- Phases
- Phase 4
- Enrollment
- 3,626 participants, actual
- Lead sponsor
- University of California, San Francisco
- Conditions
- Anesthesia, Surgery, Hypotension
- Interventions
- Norepinephrine, Phenylephrine
- First posted
- 2021-03-09
- Last updated
- 2026-09-01
- Results first posted
- 2025-12-18
- Limitations and caveats
- Pragmatic trial with events recorded throughout the eHR
Source ClinicalTrials.gov
Registered outcomes8
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Number of Participants With Assigned Vasopressor Given | Anesthesia time, up to 24 hours | First line vasopressor administration will be measured as a percent of total eligible participants with assigned vasopressor given during anesthesia time, up to 24 hours |
| Secondary | Number of Participants Who Died Within 30 Days After Surgery | 30 days | Death within 30 days of surgery. |
| Secondary | Number of Participants With Acute Kidney Injury (AKI) | 7 days | AKI is measured using the Kidney Disease: Improving Global Outcomes (KDIGO) definition based on serum creatinine. Acute kidney injury is defined as an increase in serum creatinine ≥ 0.3 mg/dL within 48 hours, or an increase in serum creatinine ≥ 1.5-fold from baseline within 7 days, or initiation of renal replacement therapy within 7 days. |
| Secondary | Number of Participants With Severe Acute Kidney Injury | 7 days | Severe acute kidney injury is assessed using the KDIGO definition based on serum creatinine or need for Renal Replacement Therapy (RRT). Severe Acute Kidney Injury is defined as an increase in serum creatinine ≥ 2-fold from baseline within 7 days, or initiation of renal replacement therapy within 7 days. |
| Secondary | Hospital Length of Stay | In-hospital, up to 30 days | Days between date of surgery and hospital discharge |
| Secondary | Number of Participants With Myocardial Injury After Non-cardiac Surgery (MINS) | 7 days | Number of participants with post-operative myocardial injury defined as a troponin elevation. |
| Secondary | Adverse Cardio-renal Events | 7 days | Number of patients meeting a combined endpoint of AKI and/or MINS |
| Secondary | Rehospitalization Within 30 Days | 30 days | Patients discharge and readmitted for more than 24 hours within 30 days after surgery |
Source ClinicalTrials.gov
Outcomes8
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Number of Participants With Assigned Vasopressor Given | Anesthesia time, up to 24 hours | Participants | COUNT_OF_PARTICIPANTS | |
| SECONDARY | Number of Participants Who Died Within 30 Days After Surgery | 30 days | Participants | COUNT_OF_PARTICIPANTS | |
| SECONDARY | Number of Participants With Acute Kidney Injury (AKI) | 7 days | Participants | COUNT_OF_PARTICIPANTS | |
| SECONDARY | Number of Participants With Severe Acute Kidney Injury | 7 days | Participants | COUNT_OF_PARTICIPANTS | |
| SECONDARY | Hospital Length of Stay | In-hospital, up to 30 days | days | MEDIAN | |
| SECONDARY | Number of Participants With Myocardial Injury After Non-cardiac Surgery (MINS) | 7 days | Participants | COUNT_OF_PARTICIPANTS | |
| SECONDARY | Adverse Cardio-renal Events | 7 days | Participants | COUNT_OF_PARTICIPANTS | |
| SECONDARY | Rehospitalization Within 30 Days | 30 days | Participants | COUNT_OF_PARTICIPANTS |
Source ClinicalTrials.gov
Results by group16
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Number of Participants With Assigned Vasopressor Given | Norepinephrine | 1570 | Participants | ||
| Number of Participants With Assigned Vasopressor Given | Phenylephrine | 1627 | Participants | ||
| Number of Participants Who Died Within 30 Days After Surgery | Norepinephrine | 20 | Participants | ||
| Number of Participants Who Died Within 30 Days After Surgery | Phenylephrine | 22 | Participants | ||
| Number of Participants With Acute Kidney Injury (AKI) | Norepinephrine | 140 | Participants | ||
| Number of Participants With Acute Kidney Injury (AKI) | Phenylephrine | 135 | Participants | ||
| Number of Participants With Severe Acute Kidney Injury | Norepinephrine | 28 | Participants | ||
| Number of Participants With Severe Acute Kidney Injury | Phenylephrine | 31 | Participants | ||
| Hospital Length of Stay | Norepinephrine | 4 | Inter-Quartile Range 2.1 to 7.0 | days | |
| Hospital Length of Stay | Phenylephrine | 4.1 | Inter-Quartile Range 2.1 to 7.5 | days |
1 to 10 of 16Source ClinicalTrials.gov
See all 16 results by groupParticipant flow16
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Norepinephrine | 1,809 | |
| Overall Study | STARTED | Phenylephrine | 1,817 | |
| Overall Study | Site 1 | Norepinephrine | 845 | |
| Overall Study | Site 1 | Phenylephrine | 815 | |
| Overall Study | Site 2 | Norepinephrine | 302 | |
| Overall Study | Site 2 | Phenylephrine | 310 | |
| Overall Study | Site 3 | Norepinephrine | 110 | |
| Overall Study | Site 3 | Phenylephrine | 128 | |
| Overall Study | Site 4 | Norepinephrine | 261 | |
| Overall Study | Site 4 | Phenylephrine | 289 |
1 to 10 of 16Source ClinicalTrials.gov
See all 16 participant flowAdverse events6
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Acute Kidney Injury | Renal and urinary disorders | Norepinephrine | 140 | 1,809 | 140 |
| other | Acute Kidney Injury | Renal and urinary disorders | Phenylephrine | 135 | 1,817 | 135 |
| other | Myocardial injury | Cardiac disorders | Norepinephrine | 44 | 1,809 | 44 |
| other | Myocardial injury | Cardiac disorders | Phenylephrine | 38 | 1,817 | 38 |
| serious | mortality | Cardiac disorders | Norepinephrine | 20 | 1,809 | 20 |
| serious | mortality | Cardiac disorders | Phenylephrine | 22 | 1,817 | 22 |
Source ClinicalTrials.gov
Adverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Norepinephrine | 20 | 1,809 |
| Total, all-cause mortality | Phenylephrine | 22 | 1,817 |
| Total, other adverse events | Norepinephrine | 168 | 1,809 |
| Total, other adverse events | Phenylephrine | 159 | 1,817 |
| Total, serious adverse events | Norepinephrine | 20 | 1,809 |
| Total, serious adverse events | Phenylephrine | 22 | 1,817 |
Source ClinicalTrials.gov
Papers2
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons9
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|---|
| Norepinephrine vs Phenylephrine: Rehospitalization Within 30 Days | Trial comparisons |
| Norepinephrine vs Phenylephrine: Number of Participants With Myocardial Injury After Non-cardiac Surgery (MINS) | Trial comparisons |
| Norepinephrine vs Phenylephrine: Number of Participants Who Died Within 30 Days After Surgery | Trial comparisons |
| Norepinephrine vs Phenylephrine: Number of Participants With Severe Acute Kidney Injury | Trial comparisons |
| Norepinephrine vs Phenylephrine: Number of Participants With Assigned Vasopressor Given | Trial comparisons |
| Norepinephrine vs Phenylephrine: Number of Participants With Acute Kidney Injury (AKI) | Trial comparisons |
| Norepinephrine vs Phenylephrine: deaths from any cause | Trial comparisons |
| Norepinephrine vs Phenylephrine: Adverse Cardio-renal Events | Trial comparisons |
| Norepinephrine vs Phenylephrine: serious adverse events | Trial comparisons |
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT04789330
GET https://conductscience.org/api/trials/v1/NCT04789330/registered